Generic Dexilant SoluTab Availability
Last updated on May 7, 2025.
See also: Generic Dexilant
Dexilant SoluTab is a brand name of dexlansoprazole, approved by the FDA in the following formulation(s):
DEXILANT SOLUTAB (dexlansoprazole - tablet, orally disintegrating, delayed release;oral)
-
Manufacturer: TAKEDA PHARMS USA
Approval date: January 26, 2016
Strength(s): 30MG (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dexilant SoluTab. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Multiple PPI dosage form
Patent 8,461,187
Issued: June 11, 2013
Inventor(s): Taneja Rajneesh & Vakilynejad Majid
Assignee(s): Takeda Pharmaceuticals U.S.A., Inc.Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
Patent expiration dates:
- January 17, 2026✓
- January 17, 2026
-
Multiple PPI dosage form
Patent 8461187*PED
Issued: June 11, 2013
Inventor(s): Taneja Rajneesh & Vakilynejad Majid
Assignee(s): Takeda Pharmaceuticals U.S.A., Inc.Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
Patent expiration dates:
- July 17, 2026✓
- July 17, 2026
-
Method for producing granules
Patent 8,871,273
Issued: October 28, 2014
Inventor(s): Nagahara Naoki & Asakawa Naoki & Nonomura Muneo
Assignee(s): Takeda Pharmaceutical Company LimitedIn a production process of granules containing a biologically active substance, variation in the elution profile of the biologically active substance is reduced by heating the temperature of granules to about 50° C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent for a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cmor more, the variation in the elution profile of the biologically active substance from the granules is reduced.
Patent expiration dates:
- January 11, 2028✓
- January 11, 2028
-
Method for producing granules
Patent 8871273*PED
Issued: October 28, 2014
Inventor(s): Nagahara Naoki & Asakawa Naoki & Nonomura Muneo
Assignee(s): Takeda Pharmaceutical Company LimitedIn a production process of granules containing a biologically active substance, variation in the elution profile of the biologically active substance is reduced by heating the temperature of granules to about 50° C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent for a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cmor more, the variation in the elution profile of the biologically active substance from the granules is reduced.
Patent expiration dates:
- July 11, 2028✓
- July 11, 2028
-
Method for producing granules
Patent 9,011,926
Issued: April 21, 2015
Inventor(s): Nagahara Naoki & Asakawa Naoki & Nonomura Muneo
Assignee(s): Takeda Pharmaceutical Company LimitedIn a production process of granules containing a biologically active substance, variation in the elution profile of the biologically active substance is reduced by heating the temperature of granules to about 50° C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent for a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cmor more, the variation in the elution profile of the biologically active substance from the granules is reduced.
Patent expiration dates:
- February 24, 2026✓
- February 24, 2026
-
Multiple PPI dosage form
Patent 9,238,029
Issued: January 19, 2016
Inventor(s): Taneja Rajneesh & Vakilynejad Majid
Assignee(s): Takeda Pharmaceuticals U.S.A., Inc.Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
Patent expiration dates:
- January 17, 2026✓
- January 17, 2026
-
Orally-disintegrating solid preparation
Patent 9,241,910
Issued: January 26, 2016
Inventor(s): Kurasawa Takashi & Watanabe Yasuko & Omachi Yoshihiro
Assignee(s): Takeda Pharmaceutical Company LimitedThe present invention provides an orally-disintegrating solid preparation such as a tablet produced by tabletting fine granules showing controlled release of a pharmaceutically active ingredient and an additive, and the like, and the orally-disintegrating solid preparation containing fine granules coated with a coating layer containing a polymer affording a casting film having an elongation at break of about 100-about 700%. With the preparation, breakage of fine granules during tabletting can be suppressed in the production of an orally-disintegrating solid preparation containing fine granules showing controlled release of a pharmaceutically active ingredient.
Patent expiration dates:
- March 10, 2029✓
- March 10, 2029
More about Dexilant SoluTab (dexlansoprazole)
- Dexilant SoluTab consumer information
- Check interactions
- Compare alternatives
- Reviews (2)
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- Drug class: proton pump inhibitors
- Breastfeeding
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.